CardiAMP™ Cell Therapy for Heart Failure Trial
← catalyst calendarSponsored by BioCardia, Inc. (industry) · BCDA — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
125actual
Sites
24
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Dec 2016 | actual | When the study began enrolling |
| Primary completion | Feb 2025 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2025 | actual | The whole study's end, after follow-up |
| First posted | 2015-05-08 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure, Systolic
Interventions
- Biological: Autologous cell therapy
- Other: Sham
Primary outcome
what the primary-completion date above is the date OFA composite endpoint based on a 3-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis.
measured 12 Months
Publications
- PMID 33091520 — linked by the registry
- PMID 29803986 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BCDA's whole pipeline · Catalyst calendar · Every registered study · What changed